. Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease. Alzheimers Res Ther. 2010;2(6):32. PubMed.


Please login to recommend the paper.


Comments on this Paper

No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:


  1. EU Consortium Applies Nanotechnology to Study AD